



SPU

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF : Pozuelo
FOR : **COMPOSITIONS AND METHODS FOR
TREATING PARTICULAR CHEMICAL
ADDICTIONS AND MENTAL
ILLNESSES**
SERIAL NO. : 10/759,633
FILED : January 16, 2004
EXAMINER :
ART UNIT : 1639
CONFIRMATION NO. : 1215
ATTORNEY DOCKET NO. : **POZZ 200004-3-3**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, 1.98 and MPEP § 609, applicant(s) submit(s) the following Disclosure Statement concerning art of which the applicant(s) is (are) aware. A copy of PTO-1449 is enclosed herewith.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with the United States Patent and Trademark Office OG Notice dated 05 August 2003, waiving the requirement under 37 C.F.R. §1.98(a)(2)(i), for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003, Applicant(s) has not

enclosed copies of the cited U.S. patents with this Disclosure.

In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Under § 1.98(a)(3), no concise explanation of relevance is required for information that is in the English language. Accordingly, the enclosed require(s) no further explanation (or no translation is available).

Consideration of the appropriate paragraph(s) indicated below is respectfully requested:

☐ **WITHIN THREE MONTHS OF FILING:** Under § 1.97(b)(1), this Information Disclosure Statement is being filed within three months of the filing date of the application. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

☒ **BEFORE FIRST OFFICE ACTION:** Under § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

☐ **INTERNATIONAL SEARCH REPORT:** Under § 1.97(e)(1), the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

☐ **BEFORE FINAL ACTION/WITH FEE:** Under § 1.97(c)(2), this information shall be considered if filed before the mailing date of a final action if accompanied by a fee in the amount of \$180.00 as required by §1.17(p). Accordingly, the necessary fee accompanies this Information Disclosure Statement. Any overpayment or deficiency can be charged to Deposit Account No. 06-0308.

☒ **PRIORITY CLAIM:** The attached PTO 1449 Form includes all patents, publications, or other information previously cited by or submitted to the Office in one or more prior applications from which the present application claims priority. These one or

more prior applications are identified in the papers accompanying the filing of this application. In accordance with § 609 MPEP, only copies of art not previously submitted are enclosed.

It is respectfully requested that the attached document(s) be considered and officially cited in examination of this application.

Respectfully submitted,

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP

September 9, 2004
Date

Mark E. Bandy

Mark E. Bandy
Reg. No. 35,788
1100 Superior Avenue
Seventh Floor
Cleveland, OH 44114-2579
216/861-5582

CERTIFICATE OF MAILING

I certify that this Information Disclosure Statement and accompanying document(s) are being

☒ deposited with the United States Postal Service as First Class mail under 37 C.F.R. 1.8, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

☐ transmitted to facsimile number under 37 C.F.R. 1.8 on the date indicated below.

☐ deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated below and is addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Express Mail Label No.:	Signature <u>Mary Ann Temesvari</u>
Date <u>Sept. 10, 2004</u>	Printed Name Mary Ann Temesvari

Substitute for form 1449 PTO

COMPLETE IF KNOWN

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(Use as many sheets as necessary)

Application Number 10/759,633
Filing Date January 16, 2004
First Named Inventor Pozuelo
Art Unit 1639
Examiner Name
Attorney Docket No. POZZ 2 000004-3-3

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No. Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-3,332,950	7/1967	Blumberg et al.	
		US-3,879,555	4/1975	Pachter et al.	
		US-3,819,635	6/1974	Pachter et al.	
		US-4,117,161	9/1978	Pozuelo	
		US-4,124,715	11/1978	Pozuelo	
		US-4,165,382	8/1979	Pozuelo	
		US-4,217,353	8/1980	Smith, Jr.	
		US-4,389,415	6/1983	Scriabine	
		US-4,405,629	9/1983	Wurtman	
		US-5,177,081	1/1993	Kaminski	
		US-5,760,044	6/1998	Archer	
		US-5,789,411	8/1998	Gooberman et al.	
		US-			

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No.	Foreign Patent Document Country Code-Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		WO 9609047A1	3/1996	PCT		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T
		Database Chemical Abstracts on STN, O'Brien et al., AN 1996:224857, (1996).	
		Database Chemical Abstracts on STN, Collier et al, AN 1977:38191, (1976).	
		Database Chemical Abstracts on STN, Myers et al, AN 1968:43592, (1968).	
		Database Chemical Abstracts on STN, Kirgiz, AN 1991:116779 (corresponding to Russian patent SU 1599020, published 10/15/1990.	
		Merck Index, "Naltrexone," Eleventh Edition, 1989	
		Letter from Dr. Gordis, Director of National Institute on Alcohol Abuse and Alcoholism, February 1995, to Dept. of Health & Human Services, obtained on December 16, 1997 from www.inform.umd.edu/EdRes/Colleges/BSOS/Depts/Cesar/drugs/ENOCHLTR .	

Examiner Signature

Date Considered



Substitute for form 1449/PTO

COMPLETE IF KNOWN

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**
(Use as many sheets as necessary)

Application Number	10/759,633
Filing Date	January 16, 2004
First Named Inventor	Pozuelo
Art Unit	1639
Examiner Name	
Attorney-Docket No.	POZZ 2 000004-3-3

Sheet 2 of

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No. Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code-Number Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T
		Website entitled, "U.S. Detox Treatment for Opiate Addiction," obtained on December 16, 1997 from www.detox-center.com/	
		Website entitled, "Internet Alcohol Recovery Center," obtained on December 16, 1997 from www.med.upenn.edu/recovery/pros/reco2000.html	
		Website entitled, "NIAAA, National Institute on Alcohol Abuse and Alcoholism, Naltrexone Approved for Alcoholism Treatment," obtained on December 16, 1997 from www.niaaa.nih.gov/events/naltre/html	

N:\POZZ\200004\3B\MAT0001060V001.doc

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--